A Novel Class Of Bifunctional Immunotherapeutic That Exploit A Universal Antibody Binding Terminus (Uabt) To Recruit Endogenous Antibodies To Cells Expressing Cd38 Demonstrates Anti-Multiple Myeloma Activity In Vitro And Ex Vivo Against Patient Tumor Cells